SCHEMBL4965152

SCHEMBL4965152

CC(C)C(=O)N1CCN(c2ccc(C3(C(=O)NC4CCCCCC4)CC3)c(F)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
PDK2 Q15119 1/20 0.43
MAPT P10636 7/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
GFER P55789 1/20 0.42
NPY5R Q15761 1/20 0.41
HTT P42858 4/20 0.40
MEN1 O00255 1/20 0.40
ALOX12 P18054 2/20 0.40
EPHX2 P34913 2/20 0.39
ALDH1A1 P00352 2/20 0.39
ADAMTS5 Q9UNA0 2/20 0.38
RECQL P46063 1/20 0.38
MMP13 P45452 1/20 0.38
ADAM17 P78536 1/20 0.38
GPR174 Q9BXC1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965635 0.88 SMN1; SMN2 (0.46) LMNAKMT2AMAPTSMN1; SMN2GFER
SCHEMBL4962318 0.87 MAPT (0.47) LMNAKMT2APDK2MAPTSMN1; SMN2
SCHEMBL4964668 0.87 MAPT (0.47) LMNAKMT2APDK2MAPTSMN1; SMN2
SCHEMBL6408605 0.86 TDP1 (0.44) LMNAKMT2AMAPTSMN1; SMN2GFER
Hydrochloric Acid SCHEMBL4966853 0.82 BMPR1B (0.42) LMNAKMT2AMAPTSMN1; SMN2GFER
SCHEMBL4964877 0.79 PDK2 (0.45) KMT2APDK2MAPTSMN1; SMN2GFER
SCHEMBL4964952 0.79 PDK2 (0.45) KMT2APDK2MAPTSMN1; SMN2GFER
SCHEMBL4963030 0.77 PDK2 (0.46) LMNAKMT2ATSHRPDK2MAPT
SCHEMBL4963551 0.77 PDK2 (0.46) LMNAKMT2ATSHRPDK2MAPT
SCHEMBL5950986 0.77 SMN1; SMN2 (0.43) LMNAKMT2AMAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP claimed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP claimed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 LMNA 2255/4885KMT2A 3525/4885TSHR 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.